Ranitidine in Reflux Oesophagitis

Abstract

This study was designed to assess the effect of ranitidine on patients with symptomatic oesophageal reflux. In a double-blind comparative trial in 46 patients a twice daily dose of 150 mg ranitidine was compared with placebo. Relief of pain, endoscopic healing and histological improvement were significantly better in those treated with ranitidine. Thus, ranitidine is of value in the management of patients with reflux oesophagitis and may prevent the development of peptic stricture.

Managing heartburn at the ‘base’ of the GERD ‘iceberg’: effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids

“…The dosage regimen was based on the twice daily dosing of standard ranitidine 150 mg tablets that has been shown to significantly reduce oesophageal acid contact time and which has been FDA‐approved for the treatment of symptomatic GERD 14 . The findings of the present trial are consistent with those of earlier randomized, double‐blind, placebo‐controlled studies of standard ranitidine 150 mg tablets twice daily for 6 weeks that showed significant efficacy for heartburn relief in patients with mild‐to‐moderate reflux disease 15 –20 . The present study also confirms earlier trials demonstrating that a regimen of ranitidine 150 mg b.d.…”

Gastroesophageal reflux and asthma: a review of pathogenesis, diagnosis, and therapy

“…The lowest recommended dose for each drug is as follows: cimetidine, 400 mg; ranitidine, 150 mg; famotidine, 20 mg; and nizatidine, 150 mg, twice daily for 6–12 weeks. These regimens produced healing in 17–70% and improvement of symptoms in 32–82% of patients (94–106). Rates of improvement of 45–75% have been reported with high doses of H 2 ‐receptor antagonists (cimetidine, 800 mg; ranitidine, 300 mg; famotidine, 40 mg; nizatidine, 300 mg; all twice daily) (91, 103, 123).…”

Treatment of Reflux Oesophagitis with a Carbenoxolone/ Antacid/Alginate Preparation: A Double-Blind Controlled Trial

“…Carbenoxolone has not been compared directly with H2-receptor antagonists in the treatment of oesophagitis. Results obtained with these latter agents have varied widely when they were compared to unbuffered placebo rather than regular antacid; in some studies there has been significant improvement in symptoms and endoscopic appearances (18,19), in some in symptoms only (20,21), in some in endoscopic appearances only (22), and in some neither in symptoms nor in endoscopic appear-compliance and were also lower than those reported during treatment of gastric or duodenal ulcer, owing to the low daily dose. Concentrations were similar to those observed in patients given Pyrogastrone for oesophagitis in a previous study (6).…”